Pseudomonas Aeruginosa Infection Treatment Market Synopsis

Pseudomonas Aeruginosa Infection Treatment Market size was valued at USD 1.23 Billion in 2021 and is projected to reach USD 1.85 Billion by 2028, growing at a CAGR of 6% from 2022 to 2028.

Pseudomonas is a type of bacteria found commonly in the environment in soil and in water. There are many types of Pseudomonas but the one that most often causes infections in human beings is Pseudomonas aeruginosa, Pseudomonas aeruginosa can cause infections in the blood, lungs (pneumonia), or even in the other parts of the body after surgery. It is a serious health issue worldwide with a mortality rate ranging from 18% to 61%, Pseudomonas Aeruginosa Infection is treated by a combination of medicines and antibiotics.

• Pseudomonas aeruginosa is commonly found in the environment and can spread to people in healthcare settings when they are exposed to water or soil that is contaminated with these bacteria. Resistant strains of the germ are also very likely to spread from one person to another through contaminated hands, equipment, or surfaces.
• Pseudomonas aeruginosa has a prevalence of 7.1%–7.3% among all healthcare-associated infections. The most common site of this infection is pneumonia, and it is the most common Gram-negative organism identified in nosocomial pneumonia. The prevalence of P. aeruginosa is been increasing at a very faster rate.
• Moreover, if seen in intensive care unit (ICU) patients, these bacteria are responsible for an even higher percentage of healthcare-associated infections. A large international observational point-prevalence study of infections in ICU patients found that Pseudomonas aeruginosa represented around 16.2% of patient infections and was the cause of 23% of all ICU-acquired infections, with a respiratory source being the most common site of this infection.
• Pseudomonas aeruginosa infection cases are been largely increasing over the past decade. The treatment of Pseudomonas aeruginosa infections is generally done with antibiotics, antibiotic therapy with a number of other medicines is an important treatment. The medication for these types of infections includes aminoglycosides (gentamicin, tobramycin, amikacin, netilmicin), carbapenems, cephalosporins, fluoroquinolones, penicillin with β-lactamase inhibitors (BLI), monobactams (aztreonam), fosfomycin and polymyxins.

The Pseudomonas Aeruginosa Infection Treatment Market Trend Analysis

Increasing Prevalence of Serious Infections Caused by Pseudomonas Aeruginosa and Most of Them Being Nosocomial Infections

• The rising number of P. aeruginosa cases across the world is the primary factor that is boosting the demand for P. aeruginosa infection treatment. Today, Pseudomonas aeruginosa is one of the most common pathogens that may prove fatal, these bacteria cause severe nosocomial infections and also it is well-known for their multidrug resistance and hypervirulence. Infections caused by P. aeruginosa are critical to curate routinely. 
• According to the Global Burden of Diseases, Injuries, and Risk Factors Study, a study on 33 bacterial genera or species across 11 infectious syndromes conducted in 2019, from 13·7 million infection-related deaths in 2019, there were 7·7 million deaths associated with the 33 bacterial pathogens and 5 leading pathogens—Staphylococcus aureus, Escherichia coli, Streptococcus pneumoniae, Klebsiella pneumoniae, and Pseudomonas aeruginosa were responsible for 54·9% of deaths. The number shows how the bacteria has proved to be fatal. And such severity of infections is the main reason behind the greater demand for effective treatments for the same.
• Moreover, despite the decline in the mortality rate of P. aeruginosa infected from approximately 90% when it was first discovered in 1882 up to now which is around 54%-56%, complete control over the infections is still not possible. For instance, the Centers for Disease Control and Prevention (CDC), estimated 51,000 healthcare-associated P aeruginosa infections in US hospitals occurring each year. And hence due to emerging infections the need for treatments is also growing.

Rapidly Developing Multi-Drug Resistance (Antibiotic Resistance) In the Bacteria Along with Continued Development of Advanced Therapeutic Strategies

• Among all the nosocomial pathogens, Pseudomonas aeruginosa is recognized to be the major cause of morbidity and mortality. Pseudomonas aeruginosa infections are rising rapidly and these infections have no effective treatment. In addition to this, drug resistance (the nature of bacteria to develop resistance) is also growing rapidly across the world which has made the treatment even more complicated.
• Pseudomonas aeruginosa infections can generally be treated with antibiotics. But, now with the multi-drug resistance in Pseudomonas aeruginosa and increase in the number of these bacteria in healthcare settings like hospitals or nursing homes are making the treatment more difficult. For example, In the year 2017, multidrug-resistant P. aeruginosa caused an estimated 32,600 infections among hospitalized patients and 2,700 estimated deaths in the United States alone and further it is found that P. aeruginosa infects about 51,000 patients in the US each year, with about 6700 being multidrug-resistant
• With this, the bacteria are constantly finding new ways to resist the effects of the antibiotics used to treat the infections they cause and such a multi-drug resistant nature of pseudomonas aeruginosa has resulted in an urgent need for new research and innovation in the antibacterial field to develop the most effective treatment for such infections, and ultimately serving as an opportunity for the market of pseudomonas aeruginosa infection treatment.

Segmentation Analysis Of The Pseudomonas Aeruginosa Infection Treatment Market

Pseudomonas Aeruginosa Infection Treatment market segments cover the Treatment Type, Drug Type, Route of Administration and Distribution Channel. By Treatment Type, the Combination Treatment segment is Anticipated to Dominate the Market Over the Forecast period.

• Combination antibiotic therapy holds the largest share in the P. aeruginosa Infection Treatment Market. The reason behind the success of the segment is the extensive use of combination antibiotic therapy for severe pseudomonal infections.  Combination treatment is standard practice across many hospitals and healthcare centers when it comes to the treatment of P. aeruginosa.
• Combination therapy proves to be very effective on multi-drug resistant bacteria, some of the benefits include in vitro antibiotic synergy, prevention of the emergence of bacterial resistance while receiving therapy, and improved adequacy of empiric therapy.
• Combination therapy also helps in increasing compliance and efficacy, faster onset of action and it also reduces side effects and overall cost. These factors are leading to a rise in demand for combination therapy for the treatment of pseudomonas aeruginosa infection which is ultimately fuelling the growth of the Pseudomonas Aeruginosa Infection Treatment Market.

Regional Analysis of The Pseudomonas Aeruginosa Infection Treatment Market

North America is Expected to Dominate the Market during the Forecast period.

• Increasing healthcare-associated infections (HAI) and rising technological innovations in the medical field in North American countries are mainly expected to drive the growth of the market in the region. According to the Statistics, more than 2.8 million antimicrobial-resistant infections occur in the U.S. each year, and more than 35,000 people die as a result. Also, according to a multistate point prevalence survey conducted by CDC in 2014 shows that about 4% of hospitalized patients suffered from at least one of the HAI in the United States.  
• Further speaking about Canada, according to a report published in January 2022, each year, many Canadians acquire an infection during their hospital stay that increases mortality and that costs heavily to the healthcare system. It is estimated that around 220,000 Canadian patients develop healthcare-associated infections (HAI). Hence, such rising infection across developed countries like the US and Canada is expected to propel the market growth over the forecast period.
• In addition to this, government initiatives and funding for combatting antimicrobial resistance are continued in these countries and such implementation of national initiatives aimed at financially incentivizing the research and development (R&D) of antibiotics is boosting the market growth int the region.

Covid-19 Impact Analysis On Pseudomonas Aeruginosa Infection Treatment Market

• COVID-19 both directly and indirectly has affected hugely on mankind, although the mortality rate of the coronavirus is as low as 3%-4%, SARS-CoV-2 is known to rapidly decimate and lead to a high rate of hospitalization due to its high speed of propagation. And hence such hospital admissions during the pandemic period eventually led the patients to face hospital-acquired infections as, the coronavirus disease could put patients, particularly those having severe pneumonia, at risk of some well-known nosocomial pathogens such as Acinetobacter baumannii and Pseudomonas aeruginosa, baumannii and P. aeruginosa are among the most successful nosocomial pathogens with respective mortality rates of up to 70% and 61%.
• Pseudomonas aeruginosa is one of the most common coinfecting bacteria seen in COVID-19 patients. P. aeruginosa by being a biofilm-forming pathogen causing life-threatening chronic infections affected very negatively individuals with diseases like burn wounds, urinary tract infections, and respiratory infections during COVID-19.
• Hence, such a high mortality rate and heavy exacerbation of illness due to P. aeruginosa identified among COVID-19 patients led to a demand for advanced and stronger medications to fight the bacteria and also to lessen the effect of the coronavirus. During the pandemic, the treatments like Active and passive immunizations gained a lot of importance as being the most promising treatment options against COVID-19, P. aeruginosa infections, and also A. baumannii.

Top Key Players Covered in The Pseudomonas Aeruginosa Infection Treatment Market

• Allergan (US)
• Pfizer Inc. (US)
• Merck & Co. Inc. (US)
• AstraZeneca PLC (UK)
• Novartis AG (Switzerland)
• Lupin Pharmaceuticals Inc. (India)
• Gilead Sciences Inc. (US)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Bristol-Myers Squibb Co. (US)
• PARI Medical Holding GmbH (Germany)
• Janssen Pharmaceuticals Inc. (Belgium)
• AmpliPhi Biosciences Corp (US)
• Humanigen Inc (US) and Other Major Players

Key Industry Developments in the Pseudomonas Aeruginosa Infection Treatment Market

In December 2021, Polyphor and EnBiotix Announced Dosing of First Patient in a First-in-Human Clinical Trial of Inhaled Murepavadin, a novel-class antibiotic. In the current Phase I study murepavadin Inhalation Solution (MIS) will be administered using an eFlow ^ (R) Technology nebulizer (PARI Pharma GmbH) to investigate the safety, tolerability, and pharmacokinetics of murepavadin in healthy volunteers. It is also said that inhaled murepavadin has the potential to provide a significant advancement in the treatment of CF patients with chronic Pseudomonas aeruginosa.

In May 2021, Teva Pharmaceutical Industries Ltd., a leading multinational pharmaceutical company introduced erythromycin tablets. The company has launched medicines with the strength of 250 mg and 500 mg. Erythromycin tablets are prescribed to the patients with the bacterial infections as well as rheumatic fever and those who have an allergy to penicillin.

In April 2021, CARB-X is funding Phico Therapeutics, in Cambridge, UK, to develop a new intravenous engineered bacteriophage drug to treat ventilator-associated pneumonia that is caused by Pseudomonas aeruginosa, a serious problem in hospitals and intensive-care units. Pseudomonas aeruginosa is one of the top three antibiotic-resistant bacteria listed by the WHO as ‘priority pathogens’. The CARB-X provided around $5.3 million to support preclinical development of Phico’s SASPject PT3.9 project, plus up to $12.86 million more if the project goes successfully through safety to Phase 1 first-in-human clinical studies.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Treatment Type
 3.2 By Drug Type
 3.3 By Route of Administration
 3.4 By Distribution Channel

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: Pseudomonas Aeruginosa Infection Treatment Market by Treatment Type
 5.1 Pseudomonas Aeruginosa Infection Treatment Market Overview Snapshot and Growth Engine
 5.2 Pseudomonas Aeruginosa Infection Treatment Market Overview
 5.3 Monotherapy
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2016-2028F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Monotherapy: Geographic Segmentation
 5.4 Combination Therapy
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2016-2028F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Combination Therapy: Geographic Segmentation

Chapter 6: Pseudomonas Aeruginosa Infection Treatment Market by Drug Type
 6.1 Pseudomonas Aeruginosa Infection Treatment Market Overview Snapshot and Growth Engine
 6.2 Pseudomonas Aeruginosa Infection Treatment Market Overview
 6.3 Cephalosporin
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2016-2028F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Cephalosporin: Geographic Segmentation
 6.4 Aminoglycoside
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2016-2028F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Aminoglycoside: Geographic Segmentation
 6.5 Carbapenem
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size (2016-2028F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Carbapenem: Geographic Segmentation
 6.6 Monobactam
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size (2016-2028F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Monobactam: Geographic Segmentation
 6.7 Others
  6.7.1 Introduction and Market Overview
  6.7.2 Historic and Forecasted Market Size (2016-2028F)
  6.7.3 Key Market Trends, Growth Factors and Opportunities
  6.7.4 Others: Geographic Segmentation

Chapter 7: Pseudomonas Aeruginosa Infection Treatment Market by Route of Administration
 7.1 Pseudomonas Aeruginosa Infection Treatment Market Overview Snapshot and Growth Engine
 7.2 Pseudomonas Aeruginosa Infection Treatment Market Overview
 7.3 Nasal
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size (2016-2028F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Nasal: Geographic Segmentation
 7.4 Oral
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size (2016-2028F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Oral: Geographic Segmentation
 7.5 Intravenous
  7.5.1 Introduction and Market Overview
  7.5.2 Historic and Forecasted Market Size (2016-2028F)
  7.5.3 Key Market Trends, Growth Factors and Opportunities
  7.5.4 Intravenous: Geographic Segmentation

Chapter 8: Pseudomonas Aeruginosa Infection Treatment Market by Distribution Channel
 8.1 Pseudomonas Aeruginosa Infection Treatment Market Overview Snapshot and Growth Engine
 8.2 Pseudomonas Aeruginosa Infection Treatment Market Overview
 8.3 Hospital Pharmacy
  8.3.1 Introduction and Market Overview
  8.3.2 Historic and Forecasted Market Size (2016-2028F)
  8.3.3 Key Market Trends, Growth Factors and Opportunities
  8.3.4 Hospital Pharmacy: Geographic Segmentation
 8.4 Retail Pharmacy
  8.4.1 Introduction and Market Overview
  8.4.2 Historic and Forecasted Market Size (2016-2028F)
  8.4.3 Key Market Trends, Growth Factors and Opportunities
  8.4.4 Retail Pharmacy: Geographic Segmentation
 8.5 Online Pharmacy
  8.5.1 Introduction and Market Overview
  8.5.2 Historic and Forecasted Market Size (2016-2028F)
  8.5.3 Key Market Trends, Growth Factors and Opportunities
  8.5.4 Online Pharmacy: Geographic Segmentation

Chapter 9: Company Profiles and Competitive Analysis
 9.1 Competitive Landscape
  9.1.1 Competitive Positioning
  9.1.2 Pseudomonas Aeruginosa Infection Treatment Sales and Market Share By Players
  9.1.3 Industry BCG Matrix
  9.1.4 Heat Map Analysis
  9.1.5 Pseudomonas Aeruginosa Infection Treatment Industry Concentration Ratio (CR5 and HHI)
  9.1.6 Top 5 Pseudomonas Aeruginosa Infection Treatment Players Market Share
  9.1.7 Mergers and Acquisitions
  9.1.8 Business Strategies By Top Players
 9.2 ALLERGAN (US)
  9.2.1 Company Overview
  9.2.2 Key Executives
  9.2.3 Company Snapshot
  9.2.4 Operating Business Segments
  9.2.5 Product Portfolio
  9.2.6 Business Performance
  9.2.7 Key Strategic Moves and Recent Developments
  9.2.8 SWOT Analysis
 9.3 PFIZER INC. (US)
 9.4 MERCK & CO. INC. (US)
 9.5 ASTRAZENECA PLC (UK)
 9.6 NOVARTIS AG (SWITZERLAND)
 9.7 LUPIN PHARMACEUTICALS INC. (INDIA)
 9.8 GILEAD SCIENCES INC. (US)
 9.9 TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL)
 9.10 BRISTOL-MYERS SQUIBB CO. (US)
 9.11 PARI MEDICAL HOLDING GMBH (GERMANY)
 9.12 JANSSEN PHARMACEUTICALS INC. (BELGIUM)
 9.13 AMPLIPHI BIOSCIENCES CORP (US)
 9.14 HUMANIGEN INC (US)
 9.15 OTHER MAJOR PLAYERS

Chapter 10: Global Pseudomonas Aeruginosa Infection Treatment Market Analysis, Insights and Forecast, 2016-2028
 10.1 Market Overview
 10.2 Historic and Forecasted Market Size By Treatment Type
  10.2.1 Monotherapy
  10.2.2 Combination Therapy
 10.3 Historic and Forecasted Market Size By Drug Type
  10.3.1 Cephalosporin
  10.3.2 Aminoglycoside
  10.3.3 Carbapenem
  10.3.4 Monobactam
  10.3.5 Others
 10.4 Historic and Forecasted Market Size By Route of Administration
  10.4.1 Nasal
  10.4.2 Oral
  10.4.3 Intravenous
 10.5 Historic and Forecasted Market Size By Distribution Channel
  10.5.1 Hospital Pharmacy
  10.5.2 Retail Pharmacy
  10.5.3 Online Pharmacy

Chapter 11: North America Pseudomonas Aeruginosa Infection Treatment Market Analysis, Insights and Forecast, 2016-2028
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Treatment Type
  11.4.1 Monotherapy
  11.4.2 Combination Therapy
 11.5 Historic and Forecasted Market Size By Drug Type
  11.5.1 Cephalosporin
  11.5.2 Aminoglycoside
  11.5.3 Carbapenem
  11.5.4 Monobactam
  11.5.5 Others
 11.6 Historic and Forecasted Market Size By Route of Administration
  11.6.1 Nasal
  11.6.2 Oral
  11.6.3 Intravenous
 11.7 Historic and Forecasted Market Size By Distribution Channel
  11.7.1 Hospital Pharmacy
  11.7.2 Retail Pharmacy
  11.7.3 Online Pharmacy
 11.8 Historic and Forecast Market Size by Country
  11.8.1 U.S.
  11.8.2 Canada
  11.8.3 Mexico

Chapter 12: Europe Pseudomonas Aeruginosa Infection Treatment Market Analysis, Insights and Forecast, 2016-2028
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Treatment Type
  12.4.1 Monotherapy
  12.4.2 Combination Therapy
 12.5 Historic and Forecasted Market Size By Drug Type
  12.5.1 Cephalosporin
  12.5.2 Aminoglycoside
  12.5.3 Carbapenem
  12.5.4 Monobactam
  12.5.5 Others
 12.6 Historic and Forecasted Market Size By Route of Administration
  12.6.1 Nasal
  12.6.2 Oral
  12.6.3 Intravenous
 12.7 Historic and Forecasted Market Size By Distribution Channel
  12.7.1 Hospital Pharmacy
  12.7.2 Retail Pharmacy
  12.7.3 Online Pharmacy
 12.8 Historic and Forecast Market Size by Country
  12.8.1 Germany
  12.8.2 U.K.
  12.8.3 France
  12.8.4 Italy
  12.8.5 Russia
  12.8.6 Spain
  12.8.7 Rest of Europe

Chapter 13: Asia-Pacific Pseudomonas Aeruginosa Infection Treatment Market Analysis, Insights and Forecast, 2016-2028
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Treatment Type
  13.4.1 Monotherapy
  13.4.2 Combination Therapy
 13.5 Historic and Forecasted Market Size By Drug Type
  13.5.1 Cephalosporin
  13.5.2 Aminoglycoside
  13.5.3 Carbapenem
  13.5.4 Monobactam
  13.5.5 Others
 13.6 Historic and Forecasted Market Size By Route of Administration
  13.6.1 Nasal
  13.6.2 Oral
  13.6.3 Intravenous
 13.7 Historic and Forecasted Market Size By Distribution Channel
  13.7.1 Hospital Pharmacy
  13.7.2 Retail Pharmacy
  13.7.3 Online Pharmacy
 13.8 Historic and Forecast Market Size by Country
  13.8.1 China
  13.8.2 India
  13.8.3 Japan
  13.8.4 Singapore
  13.8.5 Australia
  13.8.6 New Zealand
  13.8.7 Rest of APAC

Chapter 14: Middle East & Africa Pseudomonas Aeruginosa Infection Treatment Market Analysis, Insights and Forecast, 2016-2028
 14.1 Key Market Trends, Growth Factors and Opportunities
 14.2 Impact of Covid-19
 14.3 Key Players
 14.4 Key Market Trends, Growth Factors and Opportunities
 14.4 Historic and Forecasted Market Size By Treatment Type
  14.4.1 Monotherapy
  14.4.2 Combination Therapy
 14.5 Historic and Forecasted Market Size By Drug Type
  14.5.1 Cephalosporin
  14.5.2 Aminoglycoside
  14.5.3 Carbapenem
  14.5.4 Monobactam
  14.5.5 Others
 14.6 Historic and Forecasted Market Size By Route of Administration
  14.6.1 Nasal
  14.6.2 Oral
  14.6.3 Intravenous
 14.7 Historic and Forecasted Market Size By Distribution Channel
  14.7.1 Hospital Pharmacy
  14.7.2 Retail Pharmacy
  14.7.3 Online Pharmacy
 14.8 Historic and Forecast Market Size by Country
  14.8.1 Turkey
  14.8.2 Saudi Arabia
  14.8.3 Iran
  14.8.4 UAE
  14.8.5 Africa
  14.8.6 Rest of MEA

Chapter 15: South America Pseudomonas Aeruginosa Infection Treatment Market Analysis, Insights and Forecast, 2016-2028
 15.1 Key Market Trends, Growth Factors and Opportunities
 15.2 Impact of Covid-19
 15.3 Key Players
 15.4 Key Market Trends, Growth Factors and Opportunities
 15.4 Historic and Forecasted Market Size By Treatment Type
  15.4.1 Monotherapy
  15.4.2 Combination Therapy
 15.5 Historic and Forecasted Market Size By Drug Type
  15.5.1 Cephalosporin
  15.5.2 Aminoglycoside
  15.5.3 Carbapenem
  15.5.4 Monobactam
  15.5.5 Others
 15.6 Historic and Forecasted Market Size By Route of Administration
  15.6.1 Nasal
  15.6.2 Oral
  15.6.3 Intravenous
 15.7 Historic and Forecasted Market Size By Distribution Channel
  15.7.1 Hospital Pharmacy
  15.7.2 Retail Pharmacy
  15.7.3 Online Pharmacy
 15.8 Historic and Forecast Market Size by Country
  15.8.1 Brazil
  15.8.2 Argentina
  15.8.3 Rest of SA

Chapter 16 Investment Analysis

Chapter 17 Analyst Viewpoint and Conclusion

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET COMPETITIVE RIVALRY
TABLE 005. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET THREAT OF NEW ENTRANTS
TABLE 006. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET THREAT OF SUBSTITUTES
TABLE 007. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET BY TREATMENT TYPE
TABLE 008. MONOTHERAPY MARKET OVERVIEW (2016-2028)
TABLE 009. COMBINATION THERAPY MARKET OVERVIEW (2016-2028)
TABLE 010. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET BY DRUG TYPE
TABLE 011. CEPHALOSPORIN MARKET OVERVIEW (2016-2028)
TABLE 012. AMINOGLYCOSIDE MARKET OVERVIEW (2016-2028)
TABLE 013. CARBAPENEM MARKET OVERVIEW (2016-2028)
TABLE 014. MONOBACTAM MARKET OVERVIEW (2016-2028)
TABLE 015. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 016. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET BY ROUTE OF ADMINISTRATION
TABLE 017. NASAL MARKET OVERVIEW (2016-2028)
TABLE 018. ORAL MARKET OVERVIEW (2016-2028)
TABLE 019. INTRAVENOUS MARKET OVERVIEW (2016-2028)
TABLE 020. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET BY DISTRIBUTION CHANNEL
TABLE 021. HOSPITAL PHARMACY MARKET OVERVIEW (2016-2028)
TABLE 022. RETAIL PHARMACY MARKET OVERVIEW (2016-2028)
TABLE 023. ONLINE PHARMACY MARKET OVERVIEW (2016-2028)
TABLE 024. NORTH AMERICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY TREATMENT TYPE (2016-2028)
TABLE 025. NORTH AMERICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY DRUG TYPE (2016-2028)
TABLE 026. NORTH AMERICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 027. NORTH AMERICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 028. N PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY COUNTRY (2016-2028)
TABLE 029. EUROPE PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY TREATMENT TYPE (2016-2028)
TABLE 030. EUROPE PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY DRUG TYPE (2016-2028)
TABLE 031. EUROPE PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 032. EUROPE PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 033. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY COUNTRY (2016-2028)
TABLE 034. ASIA PACIFIC PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY TREATMENT TYPE (2016-2028)
TABLE 035. ASIA PACIFIC PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY DRUG TYPE (2016-2028)
TABLE 036. ASIA PACIFIC PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 037. ASIA PACIFIC PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 038. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY COUNTRY (2016-2028)
TABLE 039. MIDDLE EAST & AFRICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY TREATMENT TYPE (2016-2028)
TABLE 040. MIDDLE EAST & AFRICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY DRUG TYPE (2016-2028)
TABLE 041. MIDDLE EAST & AFRICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 042. MIDDLE EAST & AFRICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 043. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY COUNTRY (2016-2028)
TABLE 044. SOUTH AMERICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY TREATMENT TYPE (2016-2028)
TABLE 045. SOUTH AMERICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY DRUG TYPE (2016-2028)
TABLE 046. SOUTH AMERICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION (2016-2028)
TABLE 047. SOUTH AMERICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL (2016-2028)
TABLE 048. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY COUNTRY (2016-2028)
TABLE 049. ALLERGAN (US): SNAPSHOT
TABLE 050. ALLERGAN (US): BUSINESS PERFORMANCE
TABLE 051. ALLERGAN (US): PRODUCT PORTFOLIO
TABLE 052. ALLERGAN (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 052. PFIZER INC. (US): SNAPSHOT
TABLE 053. PFIZER INC. (US): BUSINESS PERFORMANCE
TABLE 054. PFIZER INC. (US): PRODUCT PORTFOLIO
TABLE 055. PFIZER INC. (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 055. MERCK & CO. INC. (US): SNAPSHOT
TABLE 056. MERCK & CO. INC. (US): BUSINESS PERFORMANCE
TABLE 057. MERCK & CO. INC. (US): PRODUCT PORTFOLIO
TABLE 058. MERCK & CO. INC. (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 058. ASTRAZENECA PLC (UK): SNAPSHOT
TABLE 059. ASTRAZENECA PLC (UK): BUSINESS PERFORMANCE
TABLE 060. ASTRAZENECA PLC (UK): PRODUCT PORTFOLIO
TABLE 061. ASTRAZENECA PLC (UK): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 061. NOVARTIS AG (SWITZERLAND): SNAPSHOT
TABLE 062. NOVARTIS AG (SWITZERLAND): BUSINESS PERFORMANCE
TABLE 063. NOVARTIS AG (SWITZERLAND): PRODUCT PORTFOLIO
TABLE 064. NOVARTIS AG (SWITZERLAND): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 064. LUPIN PHARMACEUTICALS INC. (INDIA): SNAPSHOT
TABLE 065. LUPIN PHARMACEUTICALS INC. (INDIA): BUSINESS PERFORMANCE
TABLE 066. LUPIN PHARMACEUTICALS INC. (INDIA): PRODUCT PORTFOLIO
TABLE 067. LUPIN PHARMACEUTICALS INC. (INDIA): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 067. GILEAD SCIENCES INC. (US): SNAPSHOT
TABLE 068. GILEAD SCIENCES INC. (US): BUSINESS PERFORMANCE
TABLE 069. GILEAD SCIENCES INC. (US): PRODUCT PORTFOLIO
TABLE 070. GILEAD SCIENCES INC. (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 070. TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL): SNAPSHOT
TABLE 071. TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL): BUSINESS PERFORMANCE
TABLE 072. TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL): PRODUCT PORTFOLIO
TABLE 073. TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 073. BRISTOL-MYERS SQUIBB CO. (US): SNAPSHOT
TABLE 074. BRISTOL-MYERS SQUIBB CO. (US): BUSINESS PERFORMANCE
TABLE 075. BRISTOL-MYERS SQUIBB CO. (US): PRODUCT PORTFOLIO
TABLE 076. BRISTOL-MYERS SQUIBB CO. (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 076. PARI MEDICAL HOLDING GMBH (GERMANY): SNAPSHOT
TABLE 077. PARI MEDICAL HOLDING GMBH (GERMANY): BUSINESS PERFORMANCE
TABLE 078. PARI MEDICAL HOLDING GMBH (GERMANY): PRODUCT PORTFOLIO
TABLE 079. PARI MEDICAL HOLDING GMBH (GERMANY): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 079. JANSSEN PHARMACEUTICALS INC. (BELGIUM): SNAPSHOT
TABLE 080. JANSSEN PHARMACEUTICALS INC. (BELGIUM): BUSINESS PERFORMANCE
TABLE 081. JANSSEN PHARMACEUTICALS INC. (BELGIUM): PRODUCT PORTFOLIO
TABLE 082. JANSSEN PHARMACEUTICALS INC. (BELGIUM): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 082. AMPLIPHI BIOSCIENCES CORP (US): SNAPSHOT
TABLE 083. AMPLIPHI BIOSCIENCES CORP (US): BUSINESS PERFORMANCE
TABLE 084. AMPLIPHI BIOSCIENCES CORP (US): PRODUCT PORTFOLIO
TABLE 085. AMPLIPHI BIOSCIENCES CORP (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 085. HUMANIGEN INC (US): SNAPSHOT
TABLE 086. HUMANIGEN INC (US): BUSINESS PERFORMANCE
TABLE 087. HUMANIGEN INC (US): PRODUCT PORTFOLIO
TABLE 088. HUMANIGEN INC (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 088. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 089. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 090. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 091. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET OVERVIEW BY TREATMENT TYPE
FIGURE 012. MONOTHERAPY MARKET OVERVIEW (2016-2028)
FIGURE 013. COMBINATION THERAPY MARKET OVERVIEW (2016-2028)
FIGURE 014. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET OVERVIEW BY DRUG TYPE
FIGURE 015. CEPHALOSPORIN MARKET OVERVIEW (2016-2028)
FIGURE 016. AMINOGLYCOSIDE MARKET OVERVIEW (2016-2028)
FIGURE 017. CARBAPENEM MARKET OVERVIEW (2016-2028)
FIGURE 018. MONOBACTAM MARKET OVERVIEW (2016-2028)
FIGURE 019. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 020. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET OVERVIEW BY ROUTE OF ADMINISTRATION
FIGURE 021. NASAL MARKET OVERVIEW (2016-2028)
FIGURE 022. ORAL MARKET OVERVIEW (2016-2028)
FIGURE 023. INTRAVENOUS MARKET OVERVIEW (2016-2028)
FIGURE 024. PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET OVERVIEW BY DISTRIBUTION CHANNEL
FIGURE 025. HOSPITAL PHARMACY MARKET OVERVIEW (2016-2028)
FIGURE 026. RETAIL PHARMACY MARKET OVERVIEW (2016-2028)
FIGURE 027. ONLINE PHARMACY MARKET OVERVIEW (2016-2028)
FIGURE 028. NORTH AMERICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 029. EUROPE PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 030. ASIA PACIFIC PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 031. MIDDLE EAST & AFRICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 032. SOUTH AMERICA PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET OVERVIEW BY COUNTRY (2016-2028)